Altimmune, Inc. (NASDAQ:ALT) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 11.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,431,612 shares of the company's stock after selling 552,246 shares during the quarter. Vanguard Group Inc. owned about 6.23% of Altimmune worth $31,952,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ALT. B. Riley Wealth Advisors Inc. raised its holdings in shares of Altimmune by 12.9% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company's stock valued at $144,000 after buying an additional 2,687 shares during the period. Teacher Retirement System of Texas grew its stake in Altimmune by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company's stock worth $153,000 after purchasing an additional 3,423 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in Altimmune by 34.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company's stock worth $98,000 after purchasing an additional 3,500 shares during the period. Charles Schwab Investment Management Inc. raised its position in Altimmune by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company's stock valued at $1,299,000 after purchasing an additional 4,772 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in shares of Altimmune in the 4th quarter valued at about $45,000. Hedge funds and other institutional investors own 78.05% of the company's stock.

Altimmune Trading Up 3.5 %

NASDAQ:ALT traded up $0.16 during midday trading on Friday, hitting $4.56. 2,099,043 shares of the company were exchanged, compared to its average volume of 2,895,574. Altimmune, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $11.16. The company has a market capitalization of $350.80 million, a PE ratio of -2.94 and a beta of 0.91. The company has a fifty day simple moving average of $5.41 and a 200 day simple moving average of $6.73.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. As a group, equities research analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

Insider Buying and Selling at Altimmune

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the stock in a transaction on Thursday, March 13th. The shares were bought at an average cost of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now owns 10,000 shares of the company's stock, valued at approximately $52,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.10% of the stock is owned by company insiders.

Analyst Ratings Changes

ALT has been the topic of several analyst reports. Stifel Nicolaus assumed coverage on shares of Altimmune in a report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, April 3rd. Finally, William Blair reaffirmed a "market perform" rating on shares of Altimmune in a research report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Altimmune presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.